Login
Evidence Feed
About
Conferences
New
Diagnostics
New
Top genes
New
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
CANCER:
Gastroesophageal Junction Adenocarcinoma
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related cancers:
‹
Gastric Cancer (662
)
Gastroesophageal Cancer (38
)
Gastric Adenocarcinoma (35
)
Gastric Cancer (662
)
Gastroesophageal Cancer (38
)
Gastric Adenocarcinoma (35
)
›
Associations
(160)
News
Twitter
Trials
Reset Filters
VERI cancer hierarchy
x
x
x
x
HER-2 negative + PD-L1 expression
Gastroesophageal Junction Adenocarcinoma
HER-2 negative + PD-L1 expression
Gastroesophageal Junction Adenocarcinoma
pembrolizumab
Sensitive: A1 - Approval
Pharmabiz - 1 week (New A1)
pembrolizumab
Sensitive
:
A1
Pharmabiz - 1wk
pembrolizumab
Sensitive: A1 - Approval
Pharmabiz - 1 week
pembrolizumab
Sensitive
:
A1
Pharmabiz - 1 week - (New A1)
PD-L1 expression
Gastroesophageal Junction Adenocarcinoma
PD-L1 expression
Gastroesophageal Junction Adenocarcinoma
tislelizumab
Sensitive: B - Late Trials
ASCO-GI 2023 - 2 weeks (New B)
tislelizumab
Sensitive
:
B
ASCO-GI 2023 - 2wk
tislelizumab
Sensitive: B - Late Trials
ASCO-GI 2023 - 2 weeks
tislelizumab
Sensitive
:
B
ASCO-GI 2023 - 2 weeks - (New B)
CLDN18.2 positive + HER-2 negative
Gastroesophageal Junction Adenocarcinoma
CLDN18.2 positive + HER-2 negative
Gastroesophageal Junction Adenocarcinoma
IMAB362
Sensitive: B - Late Trials
ASCO-GI 2023 - 2 weeks (New B)
IMAB362
Sensitive
:
B
ASCO-GI 2023 - 2wk
IMAB362
Sensitive: B - Late Trials
ASCO-GI 2023 - 2 weeks
IMAB362
Sensitive
:
B
ASCO-GI 2023 - 2 weeks - (New B)
HER-2 negative + PD-L1 expression
Gastroesophageal Junction Adenocarcinoma
HER-2 negative + PD-L1 expression
Gastroesophageal Junction Adenocarcinoma
nivolumab
Sensitive: A1 - Approval
ASCO-GI 2023 - 2 weeks (New C3)
nivolumab
Sensitive
:
A1
ASCO-GI 2023 - 2wk
nivolumab
Sensitive: A1 - Approval
ASCO-GI 2023 - 2 weeks
nivolumab
Sensitive
:
A1
ASCO-GI 2023 - 2 weeks - (New C3)
HER-2 negative
Gastroesophageal Junction Adenocarcinoma
HER-2 negative
Gastroesophageal Junction Adenocarcinoma
camrelizumab + rivoceranib
Sensitive: C2 – Inclusion Criteria
ASCO-GI 2023 - 2 weeks (New C3)
camrelizumab + rivoceranib
Sensitive
:
C2
ASCO-GI 2023 - 2wk
camrelizumab + rivoceranib
Sensitive: C2 – Inclusion Criteria
ASCO-GI 2023 - 2 weeks
camrelizumab + rivoceranib
Sensitive
:
C2
ASCO-GI 2023 - 2 weeks - (New C3)
HER-2 overexpression
Gastroesophageal Junction Adenocarcinoma
HER-2 overexpression
Gastroesophageal Junction Adenocarcinoma
Her-VAXX
Sensitive: C2 – Inclusion Criteria
ASCO-GI 2023 - 2 weeks (New C3)
Her-VAXX
Sensitive
:
C2
ASCO-GI 2023 - 2wk
Her-VAXX
Sensitive: C2 – Inclusion Criteria
ASCO-GI 2023 - 2 weeks
Her-VAXX
Sensitive
:
C2
ASCO-GI 2023 - 2 weeks - (New C3)
CLDN18.2 positive
Gastroesophageal Junction Adenocarcinoma
CLDN18.2 positive
Gastroesophageal Junction Adenocarcinoma
CMG901
Sensitive: C2 – Inclusion Criteria
ASCO-GI 2023 - 2 weeks (New C3)
CMG901
Sensitive
:
C2
ASCO-GI 2023 - 2wk
CMG901
Sensitive: C2 – Inclusion Criteria
ASCO-GI 2023 - 2 weeks
CMG901
Sensitive
:
C2
ASCO-GI 2023 - 2 weeks - (New C3)
MSI-H/dMMR
Gastroesophageal Junction Adenocarcinoma
MSI-H/dMMR
Gastroesophageal Junction Adenocarcinoma
durvalumab + tremelimumab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
durvalumab + tremelimumab
Sensitive
:
C3
ASCO-GI 2023 - 2wk
durvalumab + tremelimumab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
durvalumab + tremelimumab
Sensitive
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
CLDN18.2 positive
Gastroesophageal Junction Adenocarcinoma
CLDN18.2 positive
Gastroesophageal Junction Adenocarcinoma
AB011
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
AB011
Sensitive
:
C3
ASCO-GI 2023 - 2wk
AB011
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
AB011
Sensitive
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
camrelizumab + pyrotinib
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
camrelizumab + pyrotinib
Sensitive
:
C3
ASCO-GI 2023 - 2wk
camrelizumab + pyrotinib
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
camrelizumab + pyrotinib
Sensitive
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
HER-2 negative
Gastroesophageal Junction Adenocarcinoma
HER-2 negative
Gastroesophageal Junction Adenocarcinoma
anlotinib + APL-502
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
anlotinib + APL-502
Sensitive
:
C3
ASCO-GI 2023 - 2wk
anlotinib + APL-502
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
anlotinib + APL-502
Sensitive
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
CAPRIN-1 expression
Gastroesophageal Junction Adenocarcinoma
CAPRIN-1 expression
Gastroesophageal Junction Adenocarcinoma
ramucirumab + TRK-950
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
ramucirumab + TRK-950
Sensitive
:
C3
ASCO-GI 2023 - 2wk
ramucirumab + TRK-950
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
ramucirumab + TRK-950
Sensitive
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
trastuzumab
Sensitive: A1 - Approval
trastuzumab
Sensitive
:
A1
trastuzumab
Sensitive: A1 - Approval
trastuzumab
Sensitive
:
A1
No biomarker
Gastroesophageal Junction Adenocarcinoma
No biomarker
Gastroesophageal Junction Adenocarcinoma
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
No biomarker
Gastroesophageal Junction Adenocarcinoma
No biomarker
Gastroesophageal Junction Adenocarcinoma
cisplatin + docetaxel + 5-fluorouracil
Sensitive: A1 - Approval
cisplatin + docetaxel + 5-fluorouracil
Sensitive
:
A1
cisplatin + docetaxel + 5-fluorouracil
Sensitive: A1 - Approval
cisplatin + docetaxel + 5-fluorouracil
Sensitive
:
A1
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
fam-trastuzumab deruxtecan-nxki
Sensitive: A1 - Approval
fam-trastuzumab deruxtecan-nxki
Sensitive
:
A1
fam-trastuzumab deruxtecan-nxki
Sensitive: A1 - Approval
fam-trastuzumab deruxtecan-nxki
Sensitive
:
A1
No biomarker
Gastroesophageal Junction Adenocarcinoma
No biomarker
Gastroesophageal Junction Adenocarcinoma
TPF
Sensitive: A1 - Approval
TPF
Sensitive
:
A1
TPF
Sensitive: A1 - Approval
TPF
Sensitive
:
A1
No biomarker
Gastroesophageal Junction Adenocarcinoma
No biomarker
Gastroesophageal Junction Adenocarcinoma
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
trastuzumab-qyyp
Sensitive: A1 - Approval
trastuzumab-qyyp
Sensitive
:
A1
trastuzumab-qyyp
Sensitive: A1 - Approval
trastuzumab-qyyp
Sensitive
:
A1
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
trastuzumab-dttb
Sensitive: A1 - Approval
trastuzumab-dttb
Sensitive
:
A1
trastuzumab-dttb
Sensitive: A1 - Approval
trastuzumab-dttb
Sensitive
:
A1
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
trastuzumab-dkst
Sensitive: A1 - Approval
trastuzumab-dkst
Sensitive
:
A1
trastuzumab-dkst
Sensitive: A1 - Approval
trastuzumab-dkst
Sensitive
:
A1
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
trastuzumab-anns
Sensitive: A1 - Approval
trastuzumab-anns
Sensitive
:
A1
trastuzumab-anns
Sensitive: A1 - Approval
trastuzumab-anns
Sensitive
:
A1
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
trastuzumab-pkrb
Sensitive: A1 - Approval
trastuzumab-pkrb
Sensitive
:
A1
trastuzumab-pkrb
Sensitive: A1 - Approval
trastuzumab-pkrb
Sensitive
:
A1
No biomarker
Gastroesophageal Junction Adenocarcinoma
No biomarker
Gastroesophageal Junction Adenocarcinoma
trifluridine/tipiracil
Sensitive: A1 - Approval
trifluridine / tipiracil
Sensitive
:
A1
trifluridine/tipiracil
Sensitive: A1 - Approval
trifluridine / tipiracil
Sensitive
:
A1
No biomarker
Gastroesophageal Junction Adenocarcinoma
No biomarker
Gastroesophageal Junction Adenocarcinoma
ramucirumab
Sensitive: A1 - Approval
ramucirumab
Sensitive
:
A1
ramucirumab
Sensitive: A1 - Approval
ramucirumab
Sensitive
:
A1
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
Zercepac (trastuzumab biosimilar)
Sensitive: A1 - Approval
Zercepac (trastuzumab biosimilar)
Sensitive
:
A1
Zercepac (trastuzumab biosimilar)
Sensitive: A1 - Approval
Zercepac (trastuzumab biosimilar)
Sensitive
:
A1
HER-2 overexpression
Gastroesophageal Junction Adenocarcinoma
HER-2 overexpression
Gastroesophageal Junction Adenocarcinoma
trastuzumab
Sensitive: A1 - Approval
trastuzumab
Sensitive
:
A1
trastuzumab
Sensitive: A1 - Approval
trastuzumab
Sensitive
:
A1
HER-2 overexpression
Gastroesophageal Junction Adenocarcinoma
HER-2 overexpression
Gastroesophageal Junction Adenocarcinoma
trastuzumab-dttb
Sensitive: A1 - Approval
trastuzumab-dttb
Sensitive
:
A1
trastuzumab-dttb
Sensitive: A1 - Approval
trastuzumab-dttb
Sensitive
:
A1
HER-2 overexpression
Gastroesophageal Junction Adenocarcinoma
HER-2 overexpression
Gastroesophageal Junction Adenocarcinoma
trastuzumab-anns
Sensitive: A1 - Approval
trastuzumab-anns
Sensitive
:
A1
trastuzumab-anns
Sensitive: A1 - Approval
trastuzumab-anns
Sensitive
:
A1
HER-2 overexpression
Gastroesophageal Junction Adenocarcinoma
HER-2 overexpression
Gastroesophageal Junction Adenocarcinoma
trastuzumab-dkst
Sensitive: A1 - Approval
trastuzumab-dkst
Sensitive
:
A1
trastuzumab-dkst
Sensitive: A1 - Approval
trastuzumab-dkst
Sensitive
:
A1
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
pembrolizumab + trastuzumab
Sensitive: A1 - Approval
pembrolizumab + trastuzumab
Sensitive
:
A1
pembrolizumab + trastuzumab
Sensitive: A1 - Approval
pembrolizumab + trastuzumab
Sensitive
:
A1
No biomarker
Gastroesophageal Junction Adenocarcinoma
No biomarker
Gastroesophageal Junction Adenocarcinoma
disitamab vedotin
Sensitive: A1 - Approval
disitamab vedotin
Sensitive
:
A1
disitamab vedotin
Sensitive: A1 - Approval
disitamab vedotin
Sensitive
:
A1
No biomarker
Gastroesophageal Junction Adenocarcinoma
No biomarker
Gastroesophageal Junction Adenocarcinoma
sintilimab
Sensitive: A1 - Approval
sintilimab
Sensitive
:
A1
sintilimab
Sensitive: A1 - Approval
sintilimab
Sensitive
:
A1
HER-2 negative
Gastroesophageal Junction Adenocarcinoma
HER-2 negative
Gastroesophageal Junction Adenocarcinoma
cisplatin + capecitabine
Sensitive: A2 - Guideline
cisplatin + capecitabine
Sensitive
:
A2
cisplatin + capecitabine
Sensitive: A2 - Guideline
cisplatin + capecitabine
Sensitive
:
A2
No biomarker
Gastroesophageal Junction Adenocarcinoma
No biomarker
Gastroesophageal Junction Adenocarcinoma
DOF
Sensitive: A2 - Guideline
DOF
Sensitive
:
A2
DOF
Sensitive: A2 - Guideline
DOF
Sensitive
:
A2
No biomarker
Gastroesophageal Junction Adenocarcinoma
No biomarker
Gastroesophageal Junction Adenocarcinoma
TCF
Sensitive: A2 - Guideline
TCF
Sensitive
:
A2
TCF
Sensitive: A2 - Guideline
TCF
Sensitive
:
A2
No biomarker
Gastroesophageal Junction Adenocarcinoma
No biomarker
Gastroesophageal Junction Adenocarcinoma
FP
Sensitive: A2 - Guideline
FP
Sensitive
:
A2
FP
Sensitive: A2 - Guideline
FP
Sensitive
:
A2
No biomarker
Gastroesophageal Junction Adenocarcinoma
No biomarker
Gastroesophageal Junction Adenocarcinoma
CaT
Sensitive: A2 - Guideline
CaT
Sensitive
:
A2
CaT
Sensitive: A2 - Guideline
CaT
Sensitive
:
A2
HER-2 negative
Gastroesophageal Junction Adenocarcinoma
HER-2 negative
Gastroesophageal Junction Adenocarcinoma
CAPOX
Sensitive: A2 - Guideline
CAPOX
Sensitive
:
A2
CAPOX
Sensitive: A2 - Guideline
CAPOX
Sensitive
:
A2
HER-2 negative
Gastroesophageal Junction Adenocarcinoma
HER-2 negative
Gastroesophageal Junction Adenocarcinoma
5-fluorouracil + oxaliplatin
Sensitive: A2 - Guideline
5-fluorouracil + oxaliplatin
Sensitive
:
A2
5-fluorouracil + oxaliplatin
Sensitive: A2 - Guideline
5-fluorouracil + oxaliplatin
Sensitive
:
A2
HER-2 negative
Gastroesophageal Junction Adenocarcinoma
HER-2 negative
Gastroesophageal Junction Adenocarcinoma
FP
Sensitive: A2 - Guideline
FP
Sensitive
:
A2
FP
Sensitive: A2 - Guideline
FP
Sensitive
:
A2
No biomarker
Gastroesophageal Junction Adenocarcinoma
No biomarker
Gastroesophageal Junction Adenocarcinoma
capecitabine
Sensitive: A2 - Guideline
capecitabine
Sensitive
:
A2
capecitabine
Sensitive: A2 - Guideline
capecitabine
Sensitive
:
A2
No biomarker
Gastroesophageal Junction Adenocarcinoma
No biomarker
Gastroesophageal Junction Adenocarcinoma
5-fluorouracil
Sensitive: A2 - Guideline
5-fluorouracil
Sensitive
:
A2
5-fluorouracil
Sensitive: A2 - Guideline
5-fluorouracil
Sensitive
:
A2
No biomarker
Gastroesophageal Junction Adenocarcinoma
No biomarker
Gastroesophageal Junction Adenocarcinoma
DP
Sensitive: A2 - Guideline
DP
Sensitive
:
A2
DP
Sensitive: A2 - Guideline
DP
Sensitive
:
A2
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login